Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Bayer to Sell Further Crop Science Businesses to BASF for Up to EUR1.7 Billion

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/26/2018 | 06:38pm CEST

By Sarah Sloat

Bayer said Thursday that it has signed an agreement to sell further Crop Science businesses to BASF for up to 1.7 billion euros ($2.07 billion) as part of its planned acquisition of Monsanto.

These businesses generated sales of EUR745 million euros in 2017, Bayer said, and about 2,500 employees will transfer to chemicals company BASF as part of the deal. Bayer will use the proceeds--after taxes and adjustments--to help finance its proposed acquisition of Monsanto.

The businesses to be divested include the global vegetable-seeds business, certain seed-treatment products, the research platform for wheat hybrids and certain glyphosate-based herbicides in Europe that are predominantly used in industrial applications, Bayer said.

In addition, three research projects in the area of herbicides and Bayer's digital-farming business will be transferred to BASF. Bayer will receive a back license for certain digital-farming applications in return, it said.

Last year, Bayer and BASF had already reached an agreement for the sale of certain Crop Science businesses for EUR5.9 billion. The businesses in that package--including Bayer's glufosinate-ammonium business and related LibertyLink technology for herbicide tolerance, along with essentially all the company's field-crop seeds businesses--generated 2017 sales of EUR1.5 billion.

The deal is subject to regulatory approval and the successful closing of Bayer's acquisition of Monsanto.

Write to Sarah Sloat at [email protected]

Stocks mentioned in the article
ChangeLast1st jan.
BASF 0.21% 84.6 Delayed Quote.-7.98%
MONSANTO 0.35% 125.14 Delayed Quote.6.82%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER
06:38pBayer to Sell Further Crop Science Businesses to BASF for Up to EUR1.7 Billio..
DJ
06:34pBayer sells more assets, bringing Monsanto deal closer
RE
06:20pBayer sells more crop science assets to BASF for 1.7 billion euros
RE
05:59pBAYER : signs agreement to sell further Crop Science businesses to BASF for up t..
PU
10:04aBAYER : 2018 Otto Bayer Award goes to Dr. Tobias Erb
PU
04/25BAYER AKTIENGESELLSCHAFT : Release according to Article 40, Section 1 of the WpH..
EQ
04/24Monsanto develops product to deactivate controversial farm chemical
RE
04/24Women's Health Market Analysis on Segment, Trend, Growth, Volume, Size, Globa..
AQ
04/20GRAIN HIGHLIGHTS : Top Stories of the Day
DJ
04/20MONSANTO : Russian nod moves Bayer closer to wrapping up Monsanto deal
RE
More news
News from SeekingAlpha
04/23OAKMARK INTERNATIONAL FUND : Q1 2018 
04/23OAKMARK GLOBAL FUND : Q1 2018 
04/20Bayer wins Russian approval for Monsanto deal 
04/17Germany to go forward with plans to restrict Monsanto weedkiller 
04/17Bayer's ILDR2 inhibitor shows encouraging action in preclinical studies, disc.. 
Financials (€)
Sales 2018 35 538 M
EBIT 2018 7 312 M
Net income 2018 4 804 M
Debt 2018 6 627 M
Yield 2018 2,89%
P/E ratio 2018 17,63
P/E ratio 2019 15,37
EV / Sales 2018 2,47x
EV / Sales 2019 2,31x
Capitalization 81 016 M
Chart BAYER
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 118 €
Spread / Average Target 21%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER-6.28%98 642
JOHNSON & JOHNSON-9.68%338 522
PFIZER2.32%220 455
NOVARTIS-8.69%202 567
ROCHE HOLDING LTD.-11.66%193 904
MERCK AND COMPANY5.97%161 967